SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)
AVAN 10.040.0%Jun 12 9:41 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Bodine who wrote (396)3/31/2002 2:11:52 AM
From: aknahow   of 513
 
Roger, I like the endpoint.

The principal endpoint is the change in
HDL cholesterol measured after the six-month booster.

////////////////////////////////////////////////////////////

To date, AVANT has received four separate Small Business Innovation Research
grants totaling $974,000 from the National Institute of Health in support of the
development of this vaccine. As further clinical data become available, we plan to
seek a corporate partner to complete development and to commercialize the
vaccine. Preclinical studies were recently published in the American Heart
Association's journal Arteriosclerosis, Thrombosis, and Vascular Biology
(Rittershaus et al., 2000).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News